Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study.
In patients with renal anemia, iron therapy can be administered intermittently or regularly at a low dose. We performed a randomized clinical trial in pediatric patients with end-stage renal failure on hemodialysis and absolute or functional iron deficiency. The study group received maintenance iron therapy according to the ferritin serum levels and the control group received intermittent 10-weekly doses. Success was defined as stabilization of ferritin levels between 100 and 800 microg/l and transferrin saturation (TSAT) between 20% and 50%, in addition to an increase in the hemoglobin level. The major reason for exclusion was iron overload. The study group received 6 mg/kg per month of parenteral iron [95% confidence interval (CI) 3.3-8.8] and the control group 14.4 mg/kg per month (95% CI 12-16.8) ( P<0.001). After 4 months of treatment, ferritin levels increased to 66 microg/l (95% CI 69-200) in the study group and to 334 microg/l (95% CI 145-522) in the control group ( P=0.009). Maintenance therapy and intermittent weekly doses were successful in 73% and 38%, respectively. After 3 months of treatment, hemoglobin levels increased to 10 g/dl, with no difference between the groups. However, in the control group the increase in hemoglobin levels was unsustained, and 3 patients needed transfusion. Patients in the control group had a higher risk of iron overload than patients in the study group (70% vs. 19%). Thus, the regimen based on assessment of serum ferritin levels was more efficient than the intermittent regimen because it increased and maintained the hemoglobin levels with lower iron doses and a lower risk of iron overload.
Ruiz-Jaramillo
Ma de la Cruz
Mde L
Mexican Institute of Social Security, León, México. maricruiz@salud.gob.mx
Guízar-Mendoza
Juan Manuel
JM
Gutiérrez-Navarro
María de Jesús
Mde J
Dubey-Ortega
Luis Antonio
LA
Amador-Licona
Norma
N
D000293:Adolescent; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology*; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D005293:Ferritins / Q000097:blood; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage* / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome
D006454:Hemoglobins; D014168:Transferrin; D005293:Ferritins; D007501:Iron